298 related articles for article (PubMed ID: 35968876)
1. A Systematic Literature Review of the Burden of Respiratory Syncytial Virus and Health Care Utilization Among United States Infants Younger Than 1 Year.
Suh M; Movva N; Bylsma LC; Fryzek JP; Nelson CB
J Infect Dis; 2022 Aug; 226(Suppl 2):S195-S212. PubMed ID: 35968876
[TBL] [Abstract][Full Text] [Related]
2. Respiratory Syncytial Virus Burden and Healthcare Utilization in United States Infants <1 Year of Age: Study of Nationally Representative Databases, 2011-2019.
Suh M; Movva N; Jiang X; Reichert H; Bylsma LC; Fryzek JP; Nelson CB
J Infect Dis; 2022 Aug; 226(Suppl 2):S184-S194. PubMed ID: 35968879
[TBL] [Abstract][Full Text] [Related]
3. RSV-related hospitalization and outpatient palivizumab use in very preterm (born at <29 wGA) infants: 2003-2020.
Packnett ER; Winer IH; Larkin H; Oladapo A; Gonzales T; Wojdyla M; Goldstein M; Smith VC
Hum Vaccin Immunother; 2022 Nov; 18(6):2140533. PubMed ID: 36412253
[TBL] [Abstract][Full Text] [Related]
4. Respiratory Syncytial Virus and All-Cause Bronchiolitis Hospitalizations Among Preterm Infants Using the Pediatric Health Information System (PHIS).
Fergie J; Suh M; Jiang X; Fryzek JP; Gonzales T
J Infect Dis; 2022 Apr; 225(7):1197-1204. PubMed ID: 32691037
[TBL] [Abstract][Full Text] [Related]
5. Risk of RSV-related hospitalization is associated with gestational age in preterm (born at 29-34 wGA) infants without outpatient palivizumab administration.
Packnett ER; Winer IH; Oladapo A; Wojdyla M
Hum Vaccin Immunother; 2023 Aug; 19(2):2252289. PubMed ID: 37828711
[TBL] [Abstract][Full Text] [Related]
6. Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants.
Forbes ML; Kumar VR; Yogev R; Wu X; Robbie GJ; Ambrose CS
Hum Vaccin Immunother; 2014; 10(10):2789-94. PubMed ID: 25483663
[TBL] [Abstract][Full Text] [Related]
7. SENTINEL1: Two-Season Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis.
Anderson EJ; DeVincenzo JP; Simões EAF; Krilov LR; Forbes ML; Pannaraj PS; Espinosa CM; Welliver RC; Wolkoff LI; Yogev R; Checchia PA; Domachowske JB; Halasa N; McBride SJ; Kumar VR; McLaurin KK; Rizzo CP; Ambrose CS
Am J Perinatol; 2020 Mar; 37(4):421-429. PubMed ID: 30991438
[TBL] [Abstract][Full Text] [Related]
8. Healthcare resource utilization and costs in the 12 months following hospitalization for respiratory syncytial virus or unspecified bronchiolitis among infants.
Ledbetter J; Brannman L; Wade SW; Gonzales T; Kong AM
J Med Econ; 2020 Feb; 23(2):139-147. PubMed ID: 31432723
[No Abstract] [Full Text] [Related]
9. Systematic Literature Review of Respiratory Syncytial Virus Laboratory Testing Practices and Incidence in United States Infants and Children <5 Years of Age.
Movva N; Suh M; Bylsma LC; Fryzek JP; Nelson CB
J Infect Dis; 2022 Aug; 226(Suppl 2):S213-S224. PubMed ID: 35968874
[TBL] [Abstract][Full Text] [Related]
10. Trends in chronologic age and infant respiratory syncytial virus hospitalization: an 8-year cohort study.
Fryzek JP; Martone WJ; Groothuis JR
Adv Ther; 2011 Mar; 28(3):195-201. PubMed ID: 21327753
[TBL] [Abstract][Full Text] [Related]
11. The 2014-2015 National Impact of the 2014 American Academy of Pediatrics Guidance for Respiratory Syncytial Virus Immunoprophylaxis on Preterm Infants Born in the United States.
Kong AM; Krilov LR; Fergie J; Goldstein M; Diakun D; Wade SW; Pavilack M; McLaurin KK
Am J Perinatol; 2018 Jan; 35(2):192-200. PubMed ID: 28881376
[TBL] [Abstract][Full Text] [Related]
12. Respiratory Syncytial Virus Prophylaxis in Infants With Congenital Diaphragmatic Hernia in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab, 2005-2017.
Kim D; Saleem M; Paes B; Mitchell I; Lanctôt KL
Clin Infect Dis; 2019 Aug; 69(6):980-986. PubMed ID: 30517603
[TBL] [Abstract][Full Text] [Related]
13. SENTINEL1: An Observational Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis.
Anderson EJ; Krilov LR; DeVincenzo JP; Checchia PA; Halasa N; Simões EA; Domachowske JB; Forbes ML; Pannaraj PS; McBride SJ; McLaurin KK; Kumar VR; Ambrose CS
Am J Perinatol; 2017 Jan; 34(1):51-61. PubMed ID: 27233106
[No Abstract] [Full Text] [Related]
14. Seasonal peaks and risk factors of respiratory syncytial virus infections related hospitalization of preterm infants in Taiwan.
Chi H; Chung CH; Lin YJ; Lin CH
PLoS One; 2018; 13(5):e0197410. PubMed ID: 29746578
[TBL] [Abstract][Full Text] [Related]
15. Palivizumab prophylaxis for respiratory syncytial virus in infants with cystic fibrosis: is there a need?
Bjornson C; Chan P; Li A; Paes B; Lanctôt KL; Mitchell I
Eur J Clin Microbiol Infect Dis; 2018 Jun; 37(6):1113-1118. PubMed ID: 29557081
[TBL] [Abstract][Full Text] [Related]
16. Mortality Among US Infants and Children Under 5 Years of Age with Respiratory Syncytial Virus and Bronchiolitis: A Systematic Literature Review.
Bylsma LC; Suh M; Movva N; Fryzek JP; Nelson CB
J Infect Dis; 2022 Aug; 226(Suppl 2):S267-S281. PubMed ID: 35968871
[TBL] [Abstract][Full Text] [Related]
17. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
[TBL] [Abstract][Full Text] [Related]
18. Burden of Severe Respiratory Syncytial Virus Disease Among 33-35 Weeks' Gestational Age Infants Born During Multiple Respiratory Syncytial Virus Seasons.
Anderson EJ; Carbonell-Estrany X; Blanken M; Lanari M; Sheridan-Pereira M; Rodgers-Gray B; Fullarton J; Rouffiac E; Vo P; Notario G; Campbell F; Paes B
Pediatr Infect Dis J; 2017 Feb; 36(2):160-167. PubMed ID: 27755464
[TBL] [Abstract][Full Text] [Related]
19. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
Romero JR
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
[TBL] [Abstract][Full Text] [Related]
20. Real-World Studies of Respiratory Syncytial Virus Hospitalizations among Moderate/Late Preterm Infants Exposed to Passive Immunoprophylaxis with Palivizumab.
Manzoni P; Baraldi E; Luna MS; Tzialla C
Am J Perinatol; 2022 Dec; 39(S 01):S7-S13. PubMed ID: 36307092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
